Oncology Data Advisor

This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.

This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.

This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.

This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.

This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.

This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.

This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.

This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.

This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.

This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.

This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.

Dr. Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, Fred Hutchinson Cancer Center, is currently serving as chair of i3 Health’s online activity and fellows meeting series, Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma. Since recording the activity, numerous updates have occurred in research for this field, with the most notable being the recent expanded approvals of idecabtagene vicleucel and ciltacabtagene autoleucel for earlier lines of therapy. In this interview, Dr. Banerjee shares additional insight into these expanded approvals and how they affect the treatment landscape for patients with multiple myeloma. Click the links below for the full activity! Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myeloma Live or Virtual Meeting Series: https://www.i3health.com/live/hemonc-fellows-lecture-series-leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myeloma

In this video, Dr. Assuntina G. Sacco, Associate Professor of Internal Medicine, Co-Director of the Hanna and Mark Gleiberman Head and Neck Cancer Center, and Disease Team Leader–Head and Neck at UC San Diego Moores Cancer Center, answers questions asked by the audience during her CME/NCPD–approved activity with i3 Health, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: New Insights and Real-World Evidence for Improved Patient Outcomes. Dr. Sacco shares insights into targeted mutations to test for, recommendations for patient education, the future of HPV therapeutic vaccines, monitoring for immune-related adverse events, and more! Claim free CME/NCPD credit for Dr. Sacco's activity here: https://www.i3health.com/course-information/recurrent-and-metastatic-hnscc-new-insights-and-real-world-evidence-for-improved-patient-outcomes

In this video, Dr. Neal Weinreb, Voluntary Associate Professor for Human Genetics at the University of Miami Miller School of Medicine, answers questions asked by the audience during his CME/NCPD–approved activity with i3 Health, Exploring Treatment Advances for Acid Sphingomyelinase Deficiency (ASMD) in Adults. Dr. Weinreb shares insights into screening for lysosomal storage disorders, genetic carrier testing, resources for family and caregivers, the future of treatment with olipudase alfa, and more. Click the links below for the full activity! Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/exploring-new-treatment-advances-for-acid-sphingomyelinase-deficiency-in-adults Live or Virtual Meeting Series: https://www.i3health.com/live/exploring-new-treatment-advances-for-acid-sphingomyelinase-deficiency-in-adults-1

In this installment of Oncology Data Advisor's Exploring Artificial Intelligence in Oncology series, Dr. Waqas Haque, Fellows Forum member and incoming Hematology/Oncology Fellow at the University of Chicago, speaks with Tracey Sikora, Co-Founder of Every Cure, a nonprofit organization whose mission is to repurpose existing FDA-approved drugs for other indications, especially in rare diseases. Check out the discussion to learn more about: • Challenges in finding treatments for rare diseases, including sparse data, low patient numbers, and lack of financial incentive for pharmaceutical companies • Every Cure’s mission to unlock the potential of drugs that are already on the market • Harnessing the latest AI and machine learning technology to structure data in a biomedical knowledge graph, looking at drugs, diseases, pathways, and targets • Barriers in drug repurposing, including clinical validation and eventual approval • The Advanced Research Projects Agency for Health (ARPA-H) grant and the importance of federal funding for rare disease research • How to develop efficient clinical trials without a large sample size • The future of AI-enabled drug discovery in oncology • And more!

In honor of Acute Myeloid Leukemia (AML) Awareness Day, Oncology Data Advisor Editorial Board and Fellows Forum members Tristan Knight, MD, FRCPC, Richa Thakur, MD, and Joseph Kalis, PharmD, BCOP, hosted a live panel discussion covering the evolving treatment landscape for AML, including: • Novel therapies and combinations such as chimeric antigen receptor (CAR) T-cell therapy and isocitrate dehydrogenase (IDH) inhibitors • The role of measurable residual disease (MRD) testing • Considerations for pediatric transplant and cellular therapy • Words of hope for patients undergoing treatment for AML Additionally, they answered live questions from the audience, including: • Do you have any first-line treatment recommendations for patients with a KMT2A mutation? • When do recommend that patients participate in a clinical trial? Take a listen to hear the panelists’ answers to these questions and their perspectives on the ever-changing therapeutic landscape for AML!

In honor of Testicular Cancer Awareness Month, Oncology Data Advisor Fellows Forum members Samuel Kareff, MD, MPH, Waqas Haque, MD, MPH, and Matthew Hadfield, DO, sat down to discuss improving early detection, minimizing toxicities of treatment, and optimizing long-term survivorship, particularly for adolescent and young adult (AYA) survivors of testicular cancer.

In celebration of Head and Neck Cancer Awareness Month this April, Oncology Data Advisor Fellows Forum and Editorial Board Members Samuel Kareff, MD, MPH; Matthew Hadfield, DO; and Nagashree Seetharamu, MD, sat down to discuss the epidemiology of head and neck squamous cell carcinomas (HNSCC), the diagnostic and treatment process of HNSCC, including: –Epidemiologic trends –Geographic distribution –Approved screening methods –Novel treatment combinations –Side effects and adverse events –Survivorship –And more!

This April, Oncology Data Advisor is raising awareness for Esophageal Cancer Awareness Month. In this interview, Oncology Data Advisor Editorial Board and Fellows Forum members Dr. Joseph Kalis, Dr. Matthew Hadfield, and Dr. Samuel Kareff discuss rising trends, treatment advances, and emerging management strategies for esophageal cancer, including the following: • The rising rate of adenocarcinoma in the context of pre-existing esophageal dysplasia and Barrett esophagus • Risk factors such as tobacco and alcohol • The roles of healthy eating and smoking cessation in esophageal cancer prevention • How the rise of immunotherapies such as pembrolizumab, nivolumab, and trastuzumab have changed practice • This month’s approval of fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2 (HER2)–positive solid tumors • Lifestyle interventions such as following the Mediterranean diet and United States Preventive Services Task Force (USPSTF) exercise guidelines that can make maximize tolerability of therapy

In this interview from the American Association for Cancer Research (AACR) 2024 Annual Meeting, Dr. Alankrita Taneja, third-year Hematology/Oncology Fellow at Roswell Park Cancer Institute and Oncology Data Fellows Forum Member, speaks with Dr. Sundar Jagannath, Professor of Medicine (Hematology and Medical Oncology) and Director of the Center of Excellence for Multiple Myeloma at the Mount Sinai Icahn School of Medicine and Tisch Cancer Institute. At the meeting, Dr. Jagannath presented results of the phase 1/2 LINKER-MM1 trial of linvoseltamab, a CD3-directed B-cell maturation antigen (BCMA) antibody under investigation for relapsed/refractory multiple myeloma. In this follow-up conversation, Dr. Jagannath shares further insights into the trial, including: • The study design, which includes triple-class–refractory patients • The unique dosing schedule of linvoseltamab, which reduces the frequency of administration to improve patient convenience • The response, survival, and measurable residual disease (MRD) negativity outcomes demonstrated in the trial, including among high-risk patients • Management of side effects, including cytokine release syndrome (CRS), neutropenia, anemia, and infections • The future role of linvoseltamab in the treatment landscape for relapsed/refractory multiple myeloma as it advances through investigation • And more!